Quantcast

Latest Factor VII Stories

2010-11-03 06:30:00

LAGUNA NIGUEL, Calif., Nov. 3, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the appointment of Karen A. Dawes to the Company's Board of Directors. Ms. Dawes brings to Inspiration over 20 years of healthcare marketing and commercialization experience, including the product launch of the only recombinant factor IX product currently on the market. Ms. Dawes will become the seventh member of Inspiration's Board of Directors. John Taylor, Co-Founder...

2010-11-01 10:00:00

HOBOKEN, N.J., Nov. 1, 2010 /PRNewswire/ -- Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl rhFVIII, to assess pharmacokinetics, efficacy, safety and...

2010-10-26 09:00:00

WAYNE, N.J., Oct. 26 /PRNewswire/ -- Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers. Fitness and healthy eating are especially important because strong muscles and a lower body weight may...

2010-10-19 11:00:00

LAGUNA NIGUEL, Calif., Oct. 19 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia. Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitors against human Factor VIII (hFVIII). The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the...

2010-08-10 13:52:00

PRINCETON, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has...

2010-08-09 09:00:00

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII...

2010-07-09 14:26:01

Underscores company's ongoing commitment to advancing hemophilia care Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the...

2010-06-28 07:00:00

WAYNE, N.J., June 28 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched FactorTrack(TM), the first customizable mobile application for people with hemophilia A. FactorTrack is a free, personal and interactive mobile application that helps make it easier to track and record hemophilia factor VIII infusions. FactorTrack captures dosing history, frequency and locations of bleeds. It allows people with hemophilia A to customize their infusion schedule based on their...

2010-03-31 11:36:30

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today. And the very treatments that can help can also put patients' lives at risk. The standard treatment is infusion with an expensively produced protein that helps the blood to clot. But in some patients the immune system fights the therapy, and in a subset of those, it sets off an allergic reaction that can result in death. Now researchers at...

2009-11-16 13:40:52

When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives. "This research illustrates international disparities in...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related